![Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents](/docs/US/2019-03-26/US10239880B2/abs.jpg.600x600.jpg)
- Patent Title: Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents
-
Application No.: US15130219Application Date: 2016-04-15
-
Publication No.: US10239880B2Publication Date: 2019-03-26
- Inventor: Aleem Gangjee
- Applicant: Duquesne University of the Holy Spirit
- Applicant Address: US PA Pittsburgh
- Assignee: Duquesne University of the Holy Spirit
- Current Assignee: Duquesne University of the Holy Spirit
- Current Assignee Address: US PA Pittsburgh
- Agency: Buchanan Ingersoll & Rooney PC
- Agent Craig G. Cochenour, Esq.
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D239/00 ; C07D239/94
![Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents](/abs-image/US/2019/03/26/US10239880B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides a compound of Formula I, and salts thereof, and a pharmaceutical composition comprising a compound of Formula I: wherein R1 is selected from the group consisting of and R2 is an alkyl group having from one to ten carbon atoms, or wherein R2 is selected from the group consisting of R1 is an alkyl group having from one to ten carbon atoms; and R is H, or an alkyl group having from one to ten carbon atoms, and R3 is H, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula V includes wherein R3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.
Public/Granted literature
Information query
